Source comparison
How to Use Tesamorelin for Body Composition Protocol: Clinical Comparisons
This table compares tesamorelin protocol variables across different research applications. Visceral fat reduction, lean mass preservation, and metabolic improvement. Dosing Frequency 2mg daily, fasted AM administration Daily fasted dosing is non-negotiable acr
This comparison does not assign a generated winner or score.
- This table compares tesamorelin protocol variables across different research applications. Visceral fat reduction, lean mass preservation, and metabolic improvement.
- Dosing Frequency
- 2mg daily, fasted AM administration
- Daily fasted dosing is non-negotiable across all body composition goals. Meal-proximate administration reduces GH pulse amplitude by 35–50%
- Cycle Duration
- 12–16 weeks on, 4–8 weeks off
- 16–20 weeks on, 6–8 weeks off
- 12 weeks on, 4 weeks off (repeated)
- Longer cycles (16–20 weeks) suit lean mass goals but increase receptor desensitisation risk. VAT reduction plateaus after week 12 in most subjects
- Training Integration
- Fasted cardio 60–90 min post-injection
- Heavy resistance training 90–120 min post-injection
- Mixed: resistance 3×/week + LISS 2×/week
- Tesamorelin's GH peak occurs 60–90 minutes post-injection. Align training modality to primary goal (lipolysis vs hypertrophy)
- Dietary Structure
- Moderate deficit (−300 to −500 kcal), 1.6g/kg protein minimum
- Maintenance or slight surplus (+100 to +200 kcal), 2.0–2.2g/kg protein
- Maintenance calories, carb cycling around training
- Protein intake below 1.6g/kg negates lean mass preservation benefits. GH is anti-catabolic only when leucine availability is adequate
- Expected Outcome (12 weeks)
- 12–18% visceral adipose tissue reduction
- 2–4kg lean mass gain, stable fat mass
- 8–12% fasting insulin reduction, improved HOMA-IR
- VAT reduction is tesamorelin's most robust outcome. Lean mass gains require concurrent resistance stimulus and are modest compared to exogenous GH